niacinamide has been researched along with Ph 1 Chromosome in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to describe pharmacokinetic (PK) properties of asciminib and to identify clinically relevant covariates impacting its exposure." | 3.11 | Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. ( Combes, FP; Ho, YY; Hoch, M; Li, YF; Lorenzo, S; Sy, SKB, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, YF | 1 |
| Combes, FP | 1 |
| Hoch, M | 1 |
| Lorenzo, S | 1 |
| Sy, SKB | 1 |
| Ho, YY | 1 |
| Zerbit, J | 1 |
| Tamburini, J | 1 |
| Goldwirt, L | 1 |
| Decroocq, J | 1 |
| Cayuela, JM | 1 |
| Chapuis, N | 1 |
| Contejean, A | 1 |
| Batista, R | 1 |
| Bouscary, D | 1 |
| Willems, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors[NCT03106779] | Phase 3 | 233 participants (Actual) | Interventional | 2017-10-26 | Active, not recruiting | ||
| A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)[NCT02081378] | Phase 1 | 326 participants (Actual) | Interventional | 2014-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by IS as measured by RQ-PCR. (NCT03106779)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asciminib | 40 |
| Bosutinib | 10 |
1 trial available for niacinamide and Ph 1 Chromosome
1 other study available for niacinamide and Ph 1 Chromosome
| Article | Year |
|---|---|
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imidazoles; Niacinamide; Philadelphia Chromosome; Precursor Cell L | 2021 |